Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Protein kinase D2 modulates hepatic insulin sensitivity in male mice

  • Rada, Patricia
  • Carceller-López, Elena
  • Hitos, Ana B.
  • Gómez-Santos, Beatriz
  • Fernández-Hernández, Constanza
  • Rey, Esther
  • Pose-Utrilla, Julia
  • García-Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Sabio, Guadalupe
  • García, Antonia
  • Aspichueta, Patricia
  • Iglesias, Teresa
  • Valverde, Ángela M.
[Objectives]: Protein kinase D (PKD) family is emerging as relevant regulator of metabolic homeostasis. However, the precise role of PKD2 in modulating hepatic insulin signaling has not been fully elucidated and it is the aim of this study., [Methods]: PKD inhibition was analyzed for insulin signaling in mouse and human hepatocytes. PKD2 was overexpressed in Huh7 hepatocytes and mouse liver, and insulin responses were evaluated. Mice with hepatocyte-specific PKD2 depletion (PKD2ΔHep) and PKD2fl/fl mice were fed a chow (CHD) or high fat diet (HFD) and glucose homeostasis and lipid metabolism were investigated., [Results]: PKD2 silencing enhanced insulin signaling in hepatocytes, an effect also found in primary hepatocytes from PKD2ΔHep mice. Conversely, a constitutively active PKD2 mutant reduced insulin-stimulated AKT phosphorylation. A more in-depth analysis revealed reduced IRS1 serine phosphorylation under basal conditions and increased IRS1 tyrosine phosphorylation in PKD2ΔHep primary hepatocytes upon insulin stimulation and, importantly PKD co-immunoprecipitates with IRS1. In vivo constitutively active PKD2 overexpression resulted in a moderate impairment of glucose homeostasis and reduced insulin signaling in the liver. On the contrary, HFD-fed PKD2ΔHep male mice displayed improved glucose and pyruvate tolerance, as well as higher peripheral insulin tolerance and enhanced hepatic insulin signaling compared to control PKD2fl/fl mice. Despite of a remodeling of hepatic lipid metabolism in HFD-fed PKD2ΔHep mice, similar steatosis grade was found in both genotypes., [Conclusions]: Results herein have unveiled an unknown role of PKD2 in the control of insulin signaling in the liver at the level of IRS1 and point PKD2 as a therapeutic target for hepatic insulin resistance., This work was funded by grants PID2023-150994OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” to PR; PID-2021-122766OB-100 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” to AMV; PID2020-115218RB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to TI; PID2021-124425OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” to PA; PDC2021-121147-I00 funded by MICIU/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR” to GS. We also acknowledge grants PI20/00837 to CG-M, PMP21/00057 to GS and PA, and PI22/01968 to ÁG-R funded by Instituto de Salud Carlos III/FEDER (Spain), and IT1476-22 funded by Basque Government, Department of Education (Spain) to PA, grants P2022/BMD-7227 funded by Comunidad de Madrid (Spain) to AMV and AG and funding from CIBERDEM (ISCIII, Spain) to AMV and CIBERNED (ISCIII, Spain) to TI, including PR and JPU research contracts, respectively. CNIC is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). EC-L is funded by Comunidad de Madrid and Fondo Social Europeo (ref. PEJ-2020-AI/BMD-18301)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk

  • Valdecantos, M. P.
  • Ruiz, Laura
  • Folgueira, Cintia
  • Rada, Patricia
  • Gómez-Santos, Beatriz
  • Solas, Maite
  • Hitos, Ana B.
  • Field, Joss
  • Francisco, Vera
  • Escalona-Garrido, Carmen
  • Zagmutt, Sebastián
  • Calderón‐Domínguez, María
  • Mera, Paula
  • García Martínez, Irma
  • Maymó-Masip, Elsa
  • Grajales, Diana
  • Alén, Rosa
  • Mora, Alfonso
  • Sáinz, Neira
  • Vides-Urrestarazu, Irene
  • Vilarrasa, Núria
  • Arbones-Mainar, José M
  • Zaragoza, Carlos
  • Moreno-Aliaga, María J.
  • Aspichueta, Patricia
  • Fernández-Veledo, Sonia
  • Vendrell, Joan
  • Serra, Dolors
  • Herrero, Laura
  • Schreiber, Renate
  • Zechner, Rudolf
  • Sabio, Guadalupe
  • Hornigold, David
  • Rondinone, Cristina M.
  • Jermutus, Lutz
  • Grimsby, J.
  • Valverde, Ángela M.
Bariatric surgery is effective for the treatment and remission of obesity and type 2 diabetes, but pharmacological approaches which exert similar metabolic adaptations are needed to avoid post-surgical complications. Here we show how G49, an oxyntomodulin (OXM) analog and dual glucagon/glucagon-like peptide-1 receptor (GCGR/GLP-1R) agonist, triggers an inter-organ crosstalk between adipose tissue, pancreas, and liver which is initiated by a rapid release of free fatty acids (FFAs) by white adipose tissue (WAT) in a GCGR-dependent manner. This interactome leads to elevations in adiponectin and fibroblast growth factor 21 (FGF21), causing WAT beiging, brown adipose tissue (BAT) activation, increased energy expenditure (EE) and weight loss. Elevation of OXM, under basal and postprandial conditions, and similar metabolic adaptations after G49 treatment were found in plasma from patients with obesity early after metabolic bariatric surgery. These results identify G49 as a potential pharmacological alternative sharing with bariatric surgery hormonal and metabolic pathways., This work was funded by grants RTI2018-094052-B-100 funded by MICIU/AEI/10.13039/501100011033/ and by ERDF “A way of making Europe” and PID-2021-122766OB-100 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU, P2022/BMD-7227 (Comunidad de Madrid, Spain) and CIBERDdem (ISCIII) to A.M.V. and M.P.V., grants PID2020-114953RB-C21 funded by MICIU/AEI/10.13039/501100011033 to L.H. and D.S., CB06/03/0001 (CIBERobn, ISCIII, Spain) and 2021SGR00367 (Government of Catalonia) to L.H., grants PID2019-106982RB-I00 funded by MICIU/AEI/10.13039/501100011033 and CB12/03/30002 (CIBERobn, ISCIII, Spain) to M.J.M.-A., grants AECC PROYE19047SABI, PMP21/00057 Infraestructura de Medicina de Precisión asociada a la Ciencia y Tecnología IMPACT-2021, Instituto de Salud Carlos III, PDC2021-121147-I00 funded by MICIU/AEI/10.13039/501100011033 and the “European Union NextGeneration/PRTR” and PID2022-138525OB-I00 funded by MICIU/AEI/10.13039/501100011033 and ERDF/EU to G.S., grant PID2021-122480OB-100 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU, and 2021 SGR 01409 (Generalitat de Catalunya) to S.F.V., grant PID2021-128737NB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU to M.S., grants PI20/00338, PI23/01133 (ISCIII, Spain), and 2021 SGR 00829 (Government of Catalunya) to J.V., grants PI17/01556 and PI22/01773 (ISCIII, Spain) to N.V., grants IT1476-22 funded by Basque Government, Department of Education and PID2021-124425OB-100 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU to P.A. and F7302 SFB‐Lipid‐Hydrolysis from the Austrian Science Fund FWF and 12CVD04 from the Leducq Foundation both to R.Z. C.F. was funded by EASO/Novo Nordisk New Investigator Award in Basic Sciences 2023, EFSD/Novo Nordisk Rising Star 2024 and IBSA Foundation Fellowship Endocrinology 2023. V.F. was supported by “Albert Renold Travel Fellowship” grant from EFSD., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Absence of MCJ/DnaJC15 promotes brown adipose tissue thermogenesis

  • Cicuéndez, Beatriz
  • Mora, Alfonso
  • López, Juan Antonio
  • Curtabbi, Andrea
  • Pérez-García, Javier
  • Porteiro, Begoña
  • Jimenez-Blasco, Daniel
  • Latorre-Muro, Pedro
  • Vo, Paula
  • Jerome, Madison
  • Gómez-Santos, Beatriz
  • Romero-Becerra, Rafael
  • Leiva, Magdalena
  • Rodríguez, Elena
  • León, Marta
  • Leiva-Vega, Luis
  • Gómez-Lado, Noemi
  • Torres, Jorge L.
  • Hernández-Cosido, Lourdes
  • Aguiar, Pablo
  • Marcos, Miguel
  • Jastroch, Martin
  • Daiber, Andreas
  • Aspichueta, Patricia
  • Bolaños, Juan P.
  • Spinelli, Jessica B.
  • Puigserver, Pere
  • Enriquez, José Antonio
  • Vázquez, Jesús
  • Folgueira, Cintia
  • Sabio, Guadalupe
Obesity poses a global health challenge, demanding a deeper understanding of adipose tissue (AT) and its mitochondria. This study describes the role of the mitochondrial protein Methylation-controlled J protein (MCJ/DnaJC15) in orchestrating brown adipose tissue (BAT) thermogenesis. Here we show how MCJ expression decreases during obesity, as evident in human and mouse adipose tissue samples. MCJKO mice, even without UCP1, a fundamental thermogenic protein, exhibit elevated BAT thermogenesis. Electron microscopy unveils changes in mitochondrial morphology resembling BAT activation. Proteomic analysis confirms these findings and suggests involvement of the eIF2α mediated stress response. The pivotal role of eIF2α is scrutinized by in vivo CRISPR deletion of eIF2α in MCJKO mice, abrogating thermogenesis. These findings uncover the importance of MCJ as a regulator of BAT thermogenesis, presenting it as a promising target for obesity therapy., We thank Electron Microscopy Facility (Centro Nacional de Biotecnología, CSIC) for preparing samples (Epon embedding), obtaining the ultrathin sections and TEM visualization. The project that gave rise to these results received the support of a fellowship from” la Caixa” Foundation (ID 100010434). The fellowship code is LCF/BQ/DR21/11880010 to B.C. C.F was funded with Sara Borrell (CD19/ 00078), NNF23SA0083952-EASO/Novo Nordisk New Investigator Award in Basic Sciences 2023, EFSD/Lilly Young Investigator Award 2022, Society for Endocrinology/Early Career Grant 2022, FSEEN/ Jóvenes endocrinólogos 2022, EFSD/Novo Nordisk Rising Star 2024, IBSA Foundation Fellowship Endocrinology 2023. This work has been supported by the following projects: PMP21/00057 funded by the Instituto de Salud Carlos III (ISCIII) - European Union (FEDER/FSE) “Una manera de hacer Europa”/ “El FSE invierte en tu futuro”/ Next Generation EU and cofunded by the European Union / Plan de Recuperación, Transformación y Resiliencia (PRTR); PID2022-138525OB-I00 de la Agencia Estatal de Investigación 10.13039/501100011033, financiado por MICIU/AEI/10.13039/501100011033 fondos FEDER and EU, PDC2021-121147-I00 and PID2019-104399RB-I00 funded by MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/Plan de Recuperación Transformación y Resiliencia -PRTR; Grant RED2022-134397-T funded by MCIN/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union NextGenerationEU/PRTR”; Fundación Jesús Serra; EFSD/Lilly Dr Sabio; 2017 Leonardo Grant BBVA Foundation (Investigadores-BBVA-2017); Comunidad de Madrid IMMUNOTHERCAN-CM S2010/BMD-2326 and B2017/BMD-373; Fundación AECC PROYE19047SABI. PreMed-Exp: PMP21/00057, PMP21/00113 Infraestructura de Medicina de Precisión asociada a la Ciencia y Tecnología IMPACT-2021, Instituto de Salud Carlos III (GS, JLT). The project leading to these results has received funding from the” la Caixa” Foundation under the project code “HR24-00581” (G.S). G.S is a Miembro Numerario of the RACVE. J.P-G was supported by the fellowship from” la Caixa” Foundation (ID 100010434), the fellowship code is LCF/BQ/DR24/12080018. A.C was supported by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement n. 713,673 and by Becas de doctorado INPhINIT “la Caixa” 2018. PLM acknowledges NIH NIDDK grant K99DK133502. M.M is supported by Instituto de Salud Carlos III (ISCIII) and the European Union project PI20/00743. P.A is supported by MCIU/AEI/FEDER, UE (PID2021-124425OB-I00) and Basque Government, Department of Education (IT1476-22) and PMP21/00080 de Medicina de Precisión asociada a la Ciencia y Tecnología IMPACT-2021, Instituto de Salud Carlos III. J.P.B is funded by MICIU/AEI (PID2022-138813OB-I00), la Caixa Foundation (grant agreement LCF/PR/HR23/52430016), Instituto de Salud Carlos III (CB16/10/00282) and the European Union’s Horizon Europe research and innovation program under the MSCA Doctoral Networks 2021 (101072759; FuEl ThEbRaiN In healtThY aging and age-related diseases, ETERNITY), AEI grants PID2019-105699RB-I00, PID2022-138813OB-I00 and PDC2021-121013-I00; HORIZON-MSCA-2021-DN-01grant 101072759; and La Caixa Research Health grant HR23-00793. PP acknowledges NIH grant R01DK136640. JAE was supported by competitive grants: PID2021-127988OB-I00 funded by MCIN/AEI/10.13039/501100011033/ FEDER, UE; Human Frontier Science Program (grant RGP0016/2018), Leducq Transatlantic Networks (17CVD04) and CIBERFES [CB16/10/00282], Centro de Investigación Biomédica. Instituto de Salud Carlos III.The CNIO and CNIC are supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation) and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

JNK1 in SF1 neurons regulates the central action of thyroid hormones on hepatic lipid metabolism

  • Fernández-González, Iara
  • Freire-Agulleiro, Oscar
  • Ferreira, Vitor
  • Silveira-Loureiro, María
  • Rial-Pensado, Eva
  • Garrido-Gil, Pablo
  • Martínez, Gloria
  • Rada, Patricia
  • Labandeira-Garcia, Jose Luis
  • Mittag, Jens
  • González-García, Ismael
  • Diéguez, Carlos
  • Nogueiras, Rubén
  • Valverde, Ángela M.
  • Davis, Roger J.
  • Sabio, Guadalupe
  • Barca-Mayo, Olga
  • López, Miguel
[Objective] Hypothalamic energy sensors, such as AMP-activated protein kinase (AMPK), and stress sensors, such as c-Jun N-terminal kinase 1 (JNK1, also known as MAPK8) modulate whole body energy balance. While the role of AMPK in steroidogenic factor 1 (SF1) neurons of the VMH has been investigated, the relevance of JNK1 in this neuronal population has not been addressed. Here, we investigated the involvement of JNK1 SF1 on energy homeostasis., [Methods] We generated mice bearing conditional JNK1 disruption through Mapk8 gene deletion in SF1 neurons (Sf1Cre/Jnk1fl/fl). Complete metabolic phenotyping, fasting/refeeding and cold challenges, as well as the central response to triiodothyronine (T3) on brown adipose tissue (BAT) thermogenesis and hepatic lipid metabolism were carried out., [Results] Sf1Cre/Jnk1fl/fl mice displayed decreased body weight, improved glucose tolerance, and reduced hepatic lipid levels. However, Sf1Cre/Jnk1fl/fl did not properly defend their temperature upon cold exposure. While central administration of T3 elicited feeding independent weight loss in both wildtype (Jnk1fl/fl) and SF1Cre/Jnk1fl/fl mice, it did not promote hepatic lipid accretion in null animals., [Conclusions] Our data demonstrated for the first time that JNK1 in SF1 neurons is necessary for the regulation of hepatic lipid metabolism, cold adaptation and central T3 actions., The research leading to these results has received funding from the Xunta de Galicia (IG-G: ED431F 2024/14; IG-G and RN ED431C 2024/10; RN: 2016-PG057; OB-M: ED431F 2020/009 and ED431C 2023/28); Ministerio de Ciencia e Innovación co-funded by the FEDER Program of EU (IG-G: PID2022-141115NA-I00; CD: PID2020-116628 GB-I00; RN: RTI2018-099413-B-I00 and RED2018-102379-T; AM-V; PID2021-122766OB-100; GS: PID2019-104399RB-I00; PMP21/00057; PDC2021-121147-I00 IMPACT-202; OB-M: PID2019-109556RB-I00; PID2022-138436OB-I00; ML: PID2021-128145NB-I00 and PDC2022-133958-I00); European Research Council (RN: ERC Synergy Grant-2019-WATCH- 810331); “la Caixa” Foundation (ID 100010434), (ML: LCF/PR/HR19/52160022 and LCF/PR/HR20/52400013); Fundación AECC (GS: PROYE19047SABI; ML: PRYGN234908LOPE). IG-G and OB-M are supported by Ramón y Cajal Awards (IG-G: RYC2021-031225-I; OB-M: RYC2018-026293-I) from the Ministerio de Ciencia e Innovación of Spain. OF-A was supported by a fellowship from Xunta de Galicia (ED481A-2019/026). CiMUS was supported by the Xunta de Galicia (2020–2023, ED431G/05). CIBER de Fisiopatología de la Obesidad y Nutrición, CIBER de Diabetes y Enfermedades Metabólicas Asociadas and CIBER de Enfermedades Neurodegenerativas are initiatives of ISCIII., Peer reviewed